LPI (LP Information)' newest research report, the “B Cell Maturation Antigen Targeted Therapy Industry Forecast” looks at past sales and reviews total world B Cell Maturation Antigen Targeted Therapy sales in 2022, providing a comprehensive analysis by region and market sector of projected B Cell Maturation Antigen Targeted Therapy sales for 2023 through 2029. With B Cell Maturation Antigen Targeted Therapy sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world B Cell Maturation Antigen Targeted Therapy industry.
This Insight Report provides a comprehensive analysis of the global B Cell Maturation Antigen Targeted Therapy landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on B Cell Maturation Antigen Targeted Therapy portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global B Cell Maturation Antigen Targeted Therapy market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for B Cell Maturation Antigen Targeted Therapy and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global B Cell Maturation Antigen Targeted Therapy.
The global B Cell Maturation Antigen Targeted Therapy market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.
United States market for B Cell Maturation Antigen Targeted Therapy is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
China market for B Cell Maturation Antigen Targeted Therapy is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Europe market for B Cell Maturation Antigen Targeted Therapy is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Global key B Cell Maturation Antigen Targeted Therapy players cover GlaxoSmithKline, Johnson & Johnson, Amgen, Seagen, AbbVie, Novartis, BioTherapeutics, Celgene and Bluebird Bio, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.
This report presents a comprehensive overview, market shares, and growth opportunities of B Cell Maturation Antigen Targeted Therapy market by product type, application, key players and key regions and countries.
Market Segmentation:
Segmentation by type
Antibody-Drug Conjugates
CAR-T Cells and Bispecific T Cell Engagers
Segmentation by application
Hospitals
Clinics
Others
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
GlaxoSmithKline
Johnson & Johnson
Amgen
Seagen
AbbVie
Novartis
BioTherapeutics
Celgene
Bluebird Bio
Bristol Mayer Squibb
Carsgen Therapeutics
Juno Therapeutics
Cogent Bioscience
CRISPR Therapeutics
Allogene Therapeutics
Harpoon Therapeutics
Poseida Therapeutics

1 Scope of the Report 1.1 Market Introduction 1.2 Years Considered 1.3 Research Objectives 1.4 Market Research Methodology 1.5 Research Process and Data Source 1.6 Economic Indicators 1.7 Currency Considered 1.8 Market Estimation Caveats 2 Executive Summary 2.1 World Market Overview 2.1.1 Global B Cell Maturation Antigen Targeted Therapy Market Size 2018-2029 2.1.2 B Cell Maturation Antigen Targeted Therapy Market Size CAGR by Region 2018 VS 2022 VS 2029 2.2 B Cell Maturation Antigen Targeted Therapy Segment by Type 2.2.1 Antibody-Drug Conjugates 2.2.2 CAR-T Cells and Bispecific T Cell Engagers 2.3 B Cell Maturation Antigen Targeted Therapy Market Size by Type 2.3.1 B Cell Maturation Antigen Targeted Therapy Market Size CAGR by Type (2018 VS 2022 VS 2029) 2.3.2 Global B Cell Maturation Antigen Targeted Therapy Market Size Market Share by Type (2018-2023) 2.4 B Cell Maturation Antigen Targeted Therapy Segment by Application 2.4.1 Hospitals 2.4.2 Clinics 2.4.3 Others 2.5 B Cell Maturation Antigen Targeted Therapy Market Size by Application 2.5.1 B Cell Maturation Antigen Targeted Therapy Market Size CAGR by Application (2018 VS 2022 VS 2029) 2.5.2 Global B Cell Maturation Antigen Targeted Therapy Market Size Market Share by Application (2018-2023) 3 B Cell Maturation Antigen Targeted Therapy Market Size by Player 3.1 B Cell Maturation Antigen Targeted Therapy Market Size Market Share by Players 3.1.1 Global B Cell Maturation Antigen Targeted Therapy Revenue by Players (2018-2023) 3.1.2 Global B Cell Maturation Antigen Targeted Therapy Revenue Market Share by Players (2018-2023) 3.2 Global B Cell Maturation Antigen Targeted Therapy Key Players Head office and Products Offered 3.3 Market Concentration Rate Analysis 3.3.1 Competition Landscape Analysis 3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2021-2023) 3.4 New Products and Potential Entrants 3.5 Mergers & Acquisitions, Expansion 4 B Cell Maturation Antigen Targeted Therapy by Regions 4.1 B Cell Maturation Antigen Targeted Therapy Market Size by Regions (2018-2023) 4.2 Americas B Cell Maturation Antigen Targeted Therapy Market Size Growth (2018-2023) 4.3 APAC B Cell Maturation Antigen Targeted Therapy Market Size Growth (2018-2023) 4.4 Europe B Cell Maturation Antigen Targeted Therapy Market Size Growth (2018-2023) 4.5 Middle East & Africa B Cell Maturation Antigen Targeted Therapy Market Size Growth (2018-2023) 5 Americas 5.1 Americas B Cell Maturation Antigen Targeted Therapy Market Size by Country (2018-2023) 5.2 Americas B Cell Maturation Antigen Targeted Therapy Market Size by Type (2018-2023) 5.3 Americas B Cell Maturation Antigen Targeted Therapy Market Size by Application (2018-2023) 5.4 United States 5.5 Canada 5.6 Mexico 5.7 Brazil 6 APAC 6.1 APAC B Cell Maturation Antigen Targeted Therapy Market Size by Region (2018-2023) 6.2 APAC B Cell Maturation Antigen Targeted Therapy Market Size by Type (2018-2023) 6.3 APAC B Cell Maturation Antigen Targeted Therapy Market Size by Application (2018-2023) 6.4 China 6.5 Japan 6.6 Korea 6.7 Southeast Asia 6.8 India 6.9 Australia 7 Europe 7.1 Europe B Cell Maturation Antigen Targeted Therapy by Country (2018-2023) 7.2 Europe B Cell Maturation Antigen Targeted Therapy Market Size by Type (2018-2023) 7.3 Europe B Cell Maturation Antigen Targeted Therapy Market Size by Application (2018-2023) 7.4 Germany 7.5 France 7.6 UK 7.7 Italy 7.8 Russia 8 Middle East & Africa 8.1 Middle East & Africa B Cell Maturation Antigen Targeted Therapy by Region (2018-2023) 8.2 Middle East & Africa B Cell Maturation Antigen Targeted Therapy Market Size by Type (2018-2023) 8.3 Middle East & Africa B Cell Maturation Antigen Targeted Therapy Market Size by Application (2018-2023) 8.4 Egypt 8.5 South Africa 8.6 Israel 8.7 Turkey 8.8 GCC Countries 9 Market Drivers, Challenges and Trends 9.1 Market Drivers & Growth Opportunities 9.2 Market Challenges & Risks 9.3 Industry Trends 10 Global B Cell Maturation Antigen Targeted Therapy Market Forecast 10.1 Global B Cell Maturation Antigen Targeted Therapy Forecast by Regions (2024-2029) 10.1.1 Global B Cell Maturation Antigen Targeted Therapy Forecast by Regions (2024-2029) 10.1.2 Americas B Cell Maturation Antigen Targeted Therapy Forecast 10.1.3 APAC B Cell Maturation Antigen Targeted Therapy Forecast 10.1.4 Europe B Cell Maturation Antigen Targeted Therapy Forecast 10.1.5 Middle East & Africa B Cell Maturation Antigen Targeted Therapy Forecast 10.2 Americas B Cell Maturation Antigen Targeted Therapy Forecast by Country (2024-2029) 10.2.1 United States B Cell Maturation Antigen Targeted Therapy Market Forecast 10.2.2 Canada B Cell Maturation Antigen Targeted Therapy Market Forecast 10.2.3 Mexico B Cell Maturation Antigen Targeted Therapy Market Forecast 10.2.4 Brazil B Cell Maturation Antigen Targeted Therapy Market Forecast 10.3 APAC B Cell Maturation Antigen Targeted Therapy Forecast by Region (2024-2029) 10.3.1 China B Cell Maturation Antigen Targeted Therapy Market Forecast 10.3.2 Japan B Cell Maturation Antigen Targeted Therapy Market Forecast 10.3.3 Korea B Cell Maturation Antigen Targeted Therapy Market Forecast 10.3.4 Southeast Asia B Cell Maturation Antigen Targeted Therapy Market Forecast 10.3.5 India B Cell Maturation Antigen Targeted Therapy Market Forecast 10.3.6 Australia B Cell Maturation Antigen Targeted Therapy Market Forecast 10.4 Europe B Cell Maturation Antigen Targeted Therapy Forecast by Country (2024-2029) 10.4.1 Germany B Cell Maturation Antigen Targeted Therapy Market Forecast 10.4.2 France B Cell Maturation Antigen Targeted Therapy Market Forecast 10.4.3 UK B Cell Maturation Antigen Targeted Therapy Market Forecast 10.4.4 Italy B Cell Maturation Antigen Targeted Therapy Market Forecast 10.4.5 Russia B Cell Maturation Antigen Targeted Therapy Market Forecast 10.5 Middle East & Africa B Cell Maturation Antigen Targeted Therapy Forecast by Region (2024-2029) 10.5.1 Egypt B Cell Maturation Antigen Targeted Therapy Market Forecast 10.5.2 South Africa B Cell Maturation Antigen Targeted Therapy Market Forecast 10.5.3 Israel B Cell Maturation Antigen Targeted Therapy Market Forecast 10.5.4 Turkey B Cell Maturation Antigen Targeted Therapy Market Forecast 10.5.5 GCC Countries B Cell Maturation Antigen Targeted Therapy Market Forecast 10.6 Global B Cell Maturation Antigen Targeted Therapy Forecast by Type (2024-2029) 10.7 Global B Cell Maturation Antigen Targeted Therapy Forecast by Application (2024-2029) 11 Key Players Analysis 11.1 GlaxoSmithKline 11.1.1 GlaxoSmithKline Company Information 11.1.2 GlaxoSmithKline B Cell Maturation Antigen Targeted Therapy Product Offered 11.1.3 GlaxoSmithKline B Cell Maturation Antigen Targeted Therapy Revenue, Gross Margin and Market Share (2018-2023) 11.1.4 GlaxoSmithKline Main Business Overview 11.1.5 GlaxoSmithKline Latest Developments 11.2 Johnson & Johnson 11.2.1 Johnson & Johnson Company Information 11.2.2 Johnson & Johnson B Cell Maturation Antigen Targeted Therapy Product Offered 11.2.3 Johnson & Johnson B Cell Maturation Antigen Targeted Therapy Revenue, Gross Margin and Market Share (2018-2023) 11.2.4 Johnson & Johnson Main Business Overview 11.2.5 Johnson & Johnson Latest Developments 11.3 Amgen 11.3.1 Amgen Company Information 11.3.2 Amgen B Cell Maturation Antigen Targeted Therapy Product Offered 11.3.3 Amgen B Cell Maturation Antigen Targeted Therapy Revenue, Gross Margin and Market Share (2018-2023) 11.3.4 Amgen Main Business Overview 11.3.5 Amgen Latest Developments 11.4 Seagen 11.4.1 Seagen Company Information 11.4.2 Seagen B Cell Maturation Antigen Targeted Therapy Product Offered 11.4.3 Seagen B Cell Maturation Antigen Targeted Therapy Revenue, Gross Margin and Market Share (2018-2023) 11.4.4 Seagen Main Business Overview 11.4.5 Seagen Latest Developments 11.5 AbbVie 11.5.1 AbbVie Company Information 11.5.2 AbbVie B Cell Maturation Antigen Targeted Therapy Product Offered 11.5.3 AbbVie B Cell Maturation Antigen Targeted Therapy Revenue, Gross Margin and Market Share (2018-2023) 11.5.4 AbbVie Main Business Overview 11.5.5 AbbVie Latest Developments 11.6 Novartis 11.6.1 Novartis Company Information 11.6.2 Novartis B Cell Maturation Antigen Targeted Therapy Product Offered 11.6.3 Novartis B Cell Maturation Antigen Targeted Therapy Revenue, Gross Margin and Market Share (2018-2023) 11.6.4 Novartis Main Business Overview 11.6.5 Novartis Latest Developments 11.7 BioTherapeutics 11.7.1 BioTherapeutics Company Information 11.7.2 BioTherapeutics B Cell Maturation Antigen Targeted Therapy Product Offered 11.7.3 BioTherapeutics B Cell Maturation Antigen Targeted Therapy Revenue, Gross Margin and Market Share (2018-2023) 11.7.4 BioTherapeutics Main Business Overview 11.7.5 BioTherapeutics Latest Developments 11.8 Celgene 11.8.1 Celgene Company Information 11.8.2 Celgene B Cell Maturation Antigen Targeted Therapy Product Offered 11.8.3 Celgene B Cell Maturation Antigen Targeted Therapy Revenue, Gross Margin and Market Share (2018-2023) 11.8.4 Celgene Main Business Overview 11.8.5 Celgene Latest Developments 11.9 Bluebird Bio 11.9.1 Bluebird Bio Company Information 11.9.2 Bluebird Bio B Cell Maturation Antigen Targeted Therapy Product Offered 11.9.3 Bluebird Bio B Cell Maturation Antigen Targeted Therapy Revenue, Gross Margin and Market Share (2018-2023) 11.9.4 Bluebird Bio Main Business Overview 11.9.5 Bluebird Bio Latest Developments 11.10 Bristol Mayer Squibb 11.10.1 Bristol Mayer Squibb Company Information 11.10.2 Bristol Mayer Squibb B Cell Maturation Antigen Targeted Therapy Product Offered 11.10.3 Bristol Mayer Squibb B Cell Maturation Antigen Targeted Therapy Revenue, Gross Margin and Market Share (2018-2023) 11.10.4 Bristol Mayer Squibb Main Business Overview 11.10.5 Bristol Mayer Squibb Latest Developments 11.11 Carsgen Therapeutics 11.11.1 Carsgen Therapeutics Company Information 11.11.2 Carsgen Therapeutics B Cell Maturation Antigen Targeted Therapy Product Offered 11.11.3 Carsgen Therapeutics B Cell Maturation Antigen Targeted Therapy Revenue, Gross Margin and Market Share (2018-2023) 11.11.4 Carsgen Therapeutics Main Business Overview 11.11.5 Carsgen Therapeutics Latest Developments 11.12 Juno Therapeutics 11.12.1 Juno Therapeutics Company Information 11.12.2 Juno Therapeutics B Cell Maturation Antigen Targeted Therapy Product Offered 11.12.3 Juno Therapeutics B Cell Maturation Antigen Targeted Therapy Revenue, Gross Margin and Market Share (2018-2023) 11.12.4 Juno Therapeutics Main Business Overview 11.12.5 Juno Therapeutics Latest Developments 11.13 Cogent Bioscience 11.13.1 Cogent Bioscience Company Information 11.13.2 Cogent Bioscience B Cell Maturation Antigen Targeted Therapy Product Offered 11.13.3 Cogent Bioscience B Cell Maturation Antigen Targeted Therapy Revenue, Gross Margin and Market Share (2018-2023) 11.13.4 Cogent Bioscience Main Business Overview 11.13.5 Cogent Bioscience Latest Developments 11.14 CRISPR Therapeutics 11.14.1 CRISPR Therapeutics Company Information 11.14.2 CRISPR Therapeutics B Cell Maturation Antigen Targeted Therapy Product Offered 11.14.3 CRISPR Therapeutics B Cell Maturation Antigen Targeted Therapy Revenue, Gross Margin and Market Share (2018-2023) 11.14.4 CRISPR Therapeutics Main Business Overview 11.14.5 CRISPR Therapeutics Latest Developments 11.15 Allogene Therapeutics 11.15.1 Allogene Therapeutics Company Information 11.15.2 Allogene Therapeutics B Cell Maturation Antigen Targeted Therapy Product Offered 11.15.3 Allogene Therapeutics B Cell Maturation Antigen Targeted Therapy Revenue, Gross Margin and Market Share (2018-2023) 11.15.4 Allogene Therapeutics Main Business Overview 11.15.5 Allogene Therapeutics Latest Developments 11.16 Harpoon Therapeutics 11.16.1 Harpoon Therapeutics Company Information 11.16.2 Harpoon Therapeutics B Cell Maturation Antigen Targeted Therapy Product Offered 11.16.3 Harpoon Therapeutics B Cell Maturation Antigen Targeted Therapy Revenue, Gross Margin and Market Share (2018-2023) 11.16.4 Harpoon Therapeutics Main Business Overview 11.16.5 Harpoon Therapeutics Latest Developments 11.17 Poseida Therapeutics 11.17.1 Poseida Therapeutics Company Information 11.17.2 Poseida Therapeutics B Cell Maturation Antigen Targeted Therapy Product Offered 11.17.3 Poseida Therapeutics B Cell Maturation Antigen Targeted Therapy Revenue, Gross Margin and Market Share (2018-2023) 11.17.4 Poseida Therapeutics Main Business Overview 11.17.5 Poseida Therapeutics Latest Developments 12 Research Findings and Conclusion